Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Subcutaneous LY3041658 in Healthy Participants
NCT04653168Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- IgG Antibodies, PD-1/PD-L1 Inhibitors, Anti-inflammatory mAbs
- Countries
- 1
01
Overview
Phase 1, open-label trial of eltrekibart in hidradenitis suppurativa (HS) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Incidence and severity of Injection Site Reaction and Visual Analog Scale Score for Injection Site Pain. Started Dec 2020; status: completed.
02
Drugs
eltrekibart
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04653168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04653168.